Phase III trial of doxorubicin / cyclophosphamide (AC), docetaxel (D), and alternating AC and D (AC-D) as front-line chemotherapy for metastatic breast cancer: Japan Clinical Oncology Group trial (JCOG9802)
Phase 3
- Conditions
- Patients with Metatatic Breast Cancer
- Registration Number
- JPRN-C000000179
- Lead Sponsor
- Japan Clinical Oncology Group(JCOG)
- Brief Summary
See the datails via "URL releasing results" above. Also the details can be seen in the JCOG website: http://www.jcog.jp/en/trials/index.html
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 450
Inclusion Criteria
Not provided
Exclusion Criteria
I. pregnant II. malignant pleural effusion, ascites, or pericardial effusion that requires emergent treatment III. Active infection IV. other cancer present within the last 5 years V. previous stem cell transplantation VI. brain metastasis that requires emergent treatment VII. relapse within 6 months after completion anthracycline or during anthracycline VIII. more than 250mg/m2 of anthracyclines IX. hypersensitivitiy of drug X. interstitial pneumonitis or pulmonary fibrosis XI. positive HBs XII. antipsychotic medication XIII. doctor's judgement
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method time to treatment failure
- Secondary Outcome Measures
Name Time Method overall survival, progression-free survival, response rate, adverse events